Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Committee for Orphan Medicinal Products (CHMP) of the European Commission has issued positive opinion for granting orphan drug status to YM BioSciences' JAK1/JAK2 inhibitor, CYT387, indicated for the treatment of primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.
Subscribe to our email newsletter
Earlier, the company has received orphan drug status for CYT387 for the treatment of myelofibrosis from the US Food and Drug Administration (FDA).
YM BioSciences president and CEO Nick Glover said CYT387 has demonstrated early efficacy in improving the key aspects of myelofibrosis including anemia, splenomegaly and a range of debilitating symptoms.
"Having our JAK inhibitor designated as an orphan drug for the treatment of myelofibrosis in Europe, in addition to our previously obtained orphan designation in the US, will help ensure that we are able to advance this drug as efficiently as possible for these patient groups," Glover said.